Blurbs

Analysts’ Top Healthcare Picks: MacroGenics (MGNX), Castle Biosciences (CSTL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MacroGenics (MGNXResearch Report), Castle Biosciences (CSTLResearch Report) and Gracell Biotechnologies (GRCLResearch Report) with bullish sentiments.

MacroGenics (MGNX)

BTIG analyst Kaveri Pohlman maintained a Buy rating on MacroGenics yesterday and set a price target of $6.00. The company’s shares closed last Thursday at $4.84, close to its 52-week low of $2.13.

According to TipRanks.com, Pohlman is ranked #7784 out of 8010 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $11.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Castle Biosciences (CSTL)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $47.00. The company’s shares closed last Thursday at $24.27.

According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of -4.3% and a 40.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Adaptive Biotechnologies.

Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $46.00, implying a 77.4% upside from current levels. In a report issued on November 2, Robert W. Baird also maintained a Buy rating on the stock with a $41.00 price target.

Gracell Biotechnologies (GRCL)

BTIG analyst Justin Zelin reiterated a Buy rating on Gracell Biotechnologies yesterday and set a price target of $18.00. The company’s shares closed last Thursday at $3.64.

According to TipRanks.com, Zelin is a 1-star analyst with an average return of -4.1% and a 39.6% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Poseida Therapeutics, and CASI Pharmaceuticals.

Gracell Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MGNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More